Adjunctive Dapagliflozin Improves Glycemic Control in T1D
Dapagliflozin, when used as adjunct treatment to insulin, improves glycemic control in patients with type 1 diabetes.
Investigators seek to determine he effects of continuous glucose monitoring on daytime and nocturnal hypoglycemia in patients with type 1 diabetes.
The NDA was supported by data from the Phase 3 inTandem clinical trial program which assessed the safety and efficacy of Zynquista in ~3000 adults with inadequately controlled type 1 ...
Investigators examined glycemic control variations in 8 high-income countries from multicenter registries in children with type 1 diabetes.